How Much Prophylaxis is Enough in Haemophilia?
Read the Carcao et al. Haemophilia 2024 publication
Prophylaxis in haemophilia is shifting from minimal factor replacement towards higher haemostatic targets that address both clinical and subclinical bleeding.
This review makes the case for individualising treatment to patient needs and examines emerging lower-dose strategies that may deliver meaningful clinical benefits while widening access to care.
What to read next
-
Updated
Outstanding Challenges in Haemophilia B Research
Astermark et al. Ther Adv Hematol 2026
-
Updated
Non-severe Haemohilia: Renewed Focus and Outcomes
Dolan et al. Semin Thromb Hemost 2025
-
Updated
Future Needs for Innovation in Haemophilia
Blatny et al. Ther Adv Hematol 2024
-
Updated
Teenagers and Adolescents With Haemophilia
Konigs et al. J Clin Med 2024
-
Updated
Synovitis and Joint Health in Patients With Haemophilia
Mancuso et al. Haemophilia 2023
-
Updated
Shared Decision Management in PUPs With Haemophilia
Astermark et al. Ther Adv Hematol 2023
-
Updated
Revised Classification of FVIII Concentrates
Hermans, et al. Blood Adv 2026
-
Updated
Targeting Higher FVIII Levels: a Narrative Review
Read the Malec et al. Haemophilia 2023 publication
-
Updated
Towards Achieving a Haemophilia-free Mind
Hermans et al. Haemophilia 2023
NP-51873